Results 51 to 60 of about 779,609 (165)

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

open access: yesJournal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor   +3 more
doaj   +1 more source

Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe [PDF]

open access: yesExpert Review of Clinical Immunology, 2015
Biosimilars are drugs developed to be highly similar to their originator biologic (or ‘reference medicinal product’) with no clinically meaningful differences in purity, efficacy or safety. Production of biologics and biosimilars is highly complex and sensitive, with any change in manufacturing process having a potential impact on efficacy and safety ...
Ulf, Müller-Ladner   +3 more
openaire   +2 more sources

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

open access: yesGastroHep, 2023
Background and Aims. Regulatory pathways compare biosimilars with originator molecules only and not with other biosimilars. With the development of multiple infliximab biosimilars, patients may be asked to transition between them.
Clare Harris   +10 more
doaj   +1 more source

Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis

open access: yesJournal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Dionicio Angel Galarza-Delgado   +8 more
doaj   +1 more source

Switching from one infliximab biosimilar ({CT}-P13) to another infliximab biosimilar ({SB}2) in patients with chronic plaque psoriasis

open access: yes, 2020
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar ...
C. Virga   +6 more
core   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis [PDF]

open access: yesJournal of Crohn's and Colitis, 2016
CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC].UC patients,
Farkas, Klaudia   +23 more
openaire   +4 more sources

Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition [PDF]

open access: yes, 2018
Funding Information: Declaration of personal interests: JG received consultancy fees and/or research support from Pfizer, Merck, Biogen, Celltrion, and Samsung Bioepis.
R. Acurcio   +63 more
core   +1 more source

Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry [PDF]

open access: yes, 2020
Background: Long-term, real-world data are required to support the use of CT-P13 in chronic conditions such as ankylosing spondylitis. However, real-world evidence may be influenced by selection bias, which can confound outcomes.
박용범   +5 more
core   +3 more sources

Biosimilar Infliximab (CT-P13 Remsima™) Is Effective in The Healing of Fistulizing Crohn’s Disease [PDF]

open access: yesJournal of Surgery, 2017
n ...
Romano, Marco   +9 more
openaire   +1 more source

Home - About - Disclaimer - Privacy